Color Kinetics Licenses Patents to TRUMPF

Published on: April 23, 2007

Color Kinetics Inc. (Nasdaq: CLRK) announced its first licensing agreement in the medical lighting field, and the first related specifically to white light applications.


The global licensing agreement is with TRUMPF GmbH + Co. KG, a $2 billion German manufacturing company.


TRUMPF will license Color Kinetics’ patents to offer the iLED surgical light, which combines intelligent microprocessor control with LEDs to produce variable color temperatures of light. The license will also apply to any future intelligent LED-based medical lights that TRUMPF may develop.


The FDA-approved iLED surgical light offers multiple benefits over conventional medical lighting systems. Its lack of radiated heat provides a more comfortable operating environment for doctors, while its variable color temperature allows more precise examination of human tissue by making contrasts more visible. iLED utilizes Color Kinetics’ patented inventions to produce LED-based white light that is adjustable from 3,500 – 5,000 Kelvin, or “warm” to “cool.” This capability has also proven helpful for doctors’ concentration and alertness during lengthy surgeries, when cooler light is preferred.


The is the 12th licensing agreement for Color Kinetics in the first quarter alone. The company has signed contracts with lighting manufacturers such as Element Labs, Lamina Ceramics and UK-based Solar GB, as well as manufacturers in vertical fields, including Ford Motor Company.


“Given the ubiquitous nature of lighting and its many diverse markets, our approach from day one has been to foster cross-industry product development and adoption by making our intellectual property accessible to third parties,” said Sims. “We believe that the physical properties and inherently ‘smart’ nature of LEDs have very broad applicability, whether for lighting fixtures, automotive and aircraft interiors, gaming machines, toys or furniture. We’ve bolstered our licensing program through the successful defense of our IP and on-going patent prosecution, and the quantity and caliber of new agreements signed indicate that our efforts have been well focused.”

(Visited 762 times, 4 visits today)

Post Your Comment

Your email address will not be published. Required fields are marked *